Learning from CD40 Candidates in Phase II to Inform Back-Translation and Optimize Novel Dendritic & Macrophage-Targeting Therapy

Time: 1:00 pm
day: Day Two


• Sharing clinical learnings from CD40-targeting antibody therapy in pancreatic cancer

• Discussing the design and outline of studies to address dendritic cells and macrophages

• Translating clinical learnings to preclinical CD40 bispecific therapy to drive stronger dendritic cell activation and cross presentation